Literature DB >> 19851757

Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms.

Nagi Idris1, Jo Neill, Ben Grayson, Benny Bang-Andersen, Louise M Witten, Lise Tøttrup Brennum, Jørn Arnt.   

Abstract

AIM: This study examined the efficacy of sertindole in comparison with a selective 5-HT(6) and a 5-HT(2A) receptor antagonist to reverse sub-chronic phencyclidine (PCP)-induced cognitive deficits in female rats.
METHODS: In the first test, adult female hooded Lister rats were trained to perform an operant reversal learning task to 90% criterion. After training, rats were treated with PCP at 2 mg/kg (i.p.) or vehicle twice daily for 7 days, followed by 7 days washout. For the second test, novel object recognition (NOR), a separate batch of rats, had the same sub-chronic PCP dosing regime and washout period. In reversal learning, rats were treated acutely with sertindole, the selective 5-HT(2A) receptor antagonist M100.907 or the selective 5-HT(6) receptor antagonist SB-742457.
RESULTS: The PCP-induced selective reversal learning deficit was significantly improved by sertindole, M100.907 and SB-742457. Sertindole also significantly improved the sub-chronic PCP-induced deficit in NOR, a test of episodic memory following a 1 min and 1 h inter-trial interval. In vivo binding studies showed that the dose-response relationship for sertindole in this study most closely correlates with affinity for 5-HT(6) receptor in vivo binding in striatum, although contribution from binding to 5-HT(2A) receptors in vivo in cortex may also provide an important mechanism.
CONCLUSION: The efficacies of selective 5-HT(2A) and 5-HT(6) receptor antagonists suggest potential mechanisms mediating the effects of sertindole, which has high affinity for these 5-HT receptor subtypes. The sertindole-induced improvement in cognitive function in this animal model suggests relevance for the management of cognitive deficit symptoms in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19851757     DOI: 10.1007/s00213-009-1702-5

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  58 in total

1.  [3H]GBR 12935 binding in vivo in mouse brain: labelling of a piperazine acceptor site.

Authors:  P H Andersen; J A Jansen; E B Nielsen
Journal:  Eur J Pharmacol       Date:  1987-11-24       Impact factor: 4.432

2.  Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.

Authors:  D L Zimbroff; J M Kane; C A Tamminga; D G Daniel; R J Mack; P J Wozniak; T B Sebree; B A Wallin; K B Kashkin
Journal:  Am J Psychiatry       Date:  1997-06       Impact factor: 18.112

3.  Clozapine but not haloperidol treatment reverses sub-chronic phencyclidine-induced disruption of conditional discrimination performance.

Authors:  Michael J Dunn; Simon Killcross
Journal:  Behav Brain Res       Date:  2006-10-05       Impact factor: 3.332

4.  The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis.

Authors:  R S Keefe; S G Silva; D O Perkins; J A Lieberman
Journal:  Schizophr Bull       Date:  1999       Impact factor: 9.306

5.  Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat.

Authors:  Z Abdul-Monim; J C Neill; G P Reynolds
Journal:  J Psychopharmacol       Date:  2007-03       Impact factor: 4.153

6.  Investigation of the effects of lamotrigine and clozapine in improving reversal-learning impairments induced by acute phencyclidine and D-amphetamine in the rat.

Authors:  N F Idris; P Repeto; J C Neill; C H Large
Journal:  Psychopharmacology (Berl)       Date:  2005-01-12       Impact factor: 4.530

7.  A preliminary investigation into the effects of antipsychotics on sub-chronic phencyclidine-induced deficits in attentional set-shifting in female rats.

Authors:  Samantha L McLean; Jonathan P Beck; Marie L Woolley; Joanna C Neill
Journal:  Behav Brain Res       Date:  2008-01-15       Impact factor: 3.332

Review 8.  Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction.

Authors:  Patricia S Goldman-Rakic; Stacy A Castner; Torgny H Svensson; Larry J Siever; Graham V Williams
Journal:  Psychopharmacology (Berl)       Date:  2004-04-30       Impact factor: 4.530

9.  Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat--a back translational study.

Authors:  Pascal Goetghebeur; Rebecca Dias
Journal:  Psychopharmacology (Berl)       Date:  2008-04-08       Impact factor: 4.530

10.  Reversal of PCP-induced learning and memory deficits in the Morris' water maze by sertindole and other antipsychotics.

Authors:  Michael Didriksen; Torben Skarsfeldt; Jørn Arnt
Journal:  Psychopharmacology (Berl)       Date:  2007-04-04       Impact factor: 4.415

View more
  26 in total

1.  Sertindole restores attentional performance and suppresses glutamate release induced by the NMDA receptor antagonist CPP.

Authors:  Mirjana Carli; Eleonora Calcagno; Ester Mainini; Jorn Arnt; Roberto W Invernizzi
Journal:  Psychopharmacology (Berl)       Date:  2010-11-04       Impact factor: 4.530

Review 2.  Prefrontal cortex executive processes affected by stress in health and disease.

Authors:  Milena Girotti; Samantha M Adler; Sarah E Bulin; Elizabeth A Fucich; Denisse Paredes; David A Morilak
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-07-06       Impact factor: 5.067

Review 3.  Animal models of schizophrenia.

Authors:  C A Jones; D J G Watson; K C F Fone
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

4.  PCP-based mice models of schizophrenia: differential behavioral, neurochemical and cellular effects of acute and subchronic treatments.

Authors:  Anna Castañé; Noemí Santana; Francesc Artigas
Journal:  Psychopharmacology (Berl)       Date:  2015-05-07       Impact factor: 4.530

5.  Negative modulation of GABAA α5 receptors by RO4938581 attenuates discrete sub-chronic and early postnatal phencyclidine (PCP)-induced cognitive deficits in rats.

Authors:  John P Redrobe; Lisbeth Elster; Kristen Frederiksen; Christoffer Bundgaard; Inge E M de Jong; Garrick P Smith; Anne Techau Bruun; Peter H Larsen; Michael Didriksen
Journal:  Psychopharmacology (Berl)       Date:  2011-11-29       Impact factor: 4.530

Review 6.  The subchronic phencyclidine rat model: relevance for the assessment of novel therapeutics for cognitive impairment associated with schizophrenia.

Authors:  Sanna K Janhunen; Heta Svärd; John Talpos; Gaurav Kumar; Thomas Steckler; Niels Plath; Linda Lerdrup; Trine Ruby; Marie Haman; Roger Wyler; Theresa M Ballard
Journal:  Psychopharmacology (Berl)       Date:  2015-06-14       Impact factor: 4.530

Review 7.  Pharmacological enhancement of memory and executive functioning in laboratory animals.

Authors:  Stan B Floresco; James D Jentsch
Journal:  Neuropsychopharmacology       Date:  2010-09-15       Impact factor: 7.853

Review 8.  Consideration of species differences in developing novel molecules as cognition enhancers.

Authors:  Jared W Young; J David Jentsch; Timothy J Bussey; Tanya L Wallace; Daniel M Hutcheson
Journal:  Neurosci Biobehav Rev       Date:  2012-10-12       Impact factor: 8.989

Review 9.  Emerging treatments in the management of schizophrenia - focus on sertindole.

Authors:  Maria Rosaria A Muscatello; Antonio Bruno; Gianluca Pandolfo; Umberto Micò; Salvatore Settineri; Rocco Zoccali
Journal:  Drug Des Devel Ther       Date:  2010-09-07       Impact factor: 4.162

10.  In vitro and in vivo characterisation of Lu AF64280, a novel, brain penetrant phosphodiesterase (PDE) 2A inhibitor: potential relevance to cognitive deficits in schizophrenia.

Authors:  John P Redrobe; Morten Jørgensen; Claus T Christoffersen; Liliana P Montezinho; Jesper F Bastlund; Martin Carnerup; Christoffer Bundgaard; Linda Lerdrup; Niels Plath
Journal:  Psychopharmacology (Berl)       Date:  2014-03-01       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.